Goldman Sachs Downgrades NGM Biopharmaceuticals to Neutral, Lowers Price Target to $4
Goldman Sachs analyst Paul Choi downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Neutral and lowers the price target from $29 to $4.
Morgan Stanley Downgrades ACM Research to Equal-Weight, Lowers Price Target to $9
Morgan Stanley analyst Charlie Chan downgrades ACM Research (NASDAQ:ACMR) from Overweight to Equal-Weight and lowers the price target from $28 to $9.
RBC Capital Downgrades Resolute Forest Prods to Sector Perform, Announces $23 Price Target
RBC Capital analyst Paul Quinn downgrades Resolute Forest Prods (NYSE:RFP) from Outperform to Sector Perform and announces $23 price target.
JP Morgan Downgrades Syneos Health to Neutral, Lowers Price Target to $53
JP Morgan analyst Tycho Peterson downgrades Syneos Health (NASDAQ:SYNH) from Overweight to Neutral and lowers the price target from $85 to $53.
Raymond James Downgrades Goodfood Market to Underperform
Raymond James analyst Michael Glen downgrades Goodfood Market (TSX:FOOD) from Market Perform to Underperform.
JMP Securities Downgrades Minerva Neurosciences to Market Perform
JMP Securities analyst Jason Butler downgrades Minerva Neurosciences (NASDAQ:NERV) from Market Outperform to Market Perform.
Piper Sandler Downgrades NGM Biopharmaceuticals to Neutral
Piper Sandler analyst Swapnil Malekar downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Overweight to Neutral.
Jefferies Downgrades NGM Biopharmaceuticals to Hold
Jefferies analyst Dennis Ding downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Hold.
NeuBase Lays Off 60% Of Workforce, Reprioritizes Pipeline To Focus On Gene Editing Tech
NeuBase Therapeutics Inc (NASDAQ:NBSE) announced restructuring plans to focus on the advancement of its platform in gene editing. The company has…
Bringing Fox And News Corp Back Together Again Scares This Analyst, Who Just Downgraded The Stock On Merger Concerns
Credit Suisse analyst Douglas Mitchelson downgraded Fox Corp (NASDAQ:FOX) (NASDAQ:FOXA) to Neutral from Outperform with a price target of $36, down from…